Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A7-neocarzinostatin
- Development stage
- Discontinued
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intraarterial, Intratumoral
01
Overview
A7-neocarzinostatin (A7-NCS) is an early-generation antibody-drug conjugate (ADC) designed for the targeted treatment of gastrointestinal malignancies, specifically colorectal, pancreatic, and gastric cancers. It consists of the murine monoclonal antibody A7, which targets a specific glycoprotein antigen expressed on these tumor cells, covalently linked to neocarzinostatin (NCS), a potent macromolecular enediyne antibiotic. NCS acts as a DNA-damaging agent, inducing strand breaks and inhibiting DNA synthesis. Developed and clinically evaluated primarily in Japan, A7-NCS was administered via intraarterial or intratumoral routes to maximize local concentration and minimize systemic toxicity. Clinical trials demonstrated its ability to localize specifically to tumor tissues and provide palliative benefits, such as tumor reduction and pain relief in patients with advanced colorectal cancer and liver metastases.
- Other names
- A7-neocarzinostatin immunoconjugateA-7-neocarzinostatin immunoconjugateA 7-neocarzinostatin immunoconjugate
02
Targets
Antigen A7 (Colorectal cancer-associated antigen A7)DNA
Beyond the preview
Go deeper on A7-neocarzinostatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on A7-neocarzinostatin.